Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Conticello, Concetta  [Clear All Filters]
2023
Fazio M, Del Fabro V, Parrinello NLaura, Allegra A, Markovic U, Botta C, Accardi F, Vincelli IDonatella, Leotta S, Elia F, et al. Multiple Myeloma in 2023 Ways: From Trials to Real Life. Curr Oncol. 2023;30(11):9710-9733.
2021
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, et al. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol. 2021.
2019
Leotta S, Pirosa MCristina, Markovic U, Scalise L, Bulla A, Sapienza G, Di Giorgio MAnn, Martino EAntonia, Pelle ACurto, Leotta V, et al. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy. Chemotherapy. 2019:1-4.
2016
Giallongo C, Tibullo D, Parrinello NL, La Cava P, Di Rosa M, Bramanti V, Di Raimondo C, Conticello C, Chiarenza A, Palumbo GA, et al. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget. 2016.
2014
Bringhen S, Petrucci MTeresa, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014.